Login / Signup

In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.

Claudia BusoneroStefano LeoneFabrizio BianchiFilippo Acconcia
Published in: Cellular oncology (Dordrecht) (2018)
We suggest that modulation of the intracellular ERα concentration in BC cells can be exploited in in silico screens to identify anti-BC drugs and uncover a re-purposing opportunity for thioridazine in the treatment of primary and metastatic ET resistant BCs.
Keyphrases